Ergoteles LLC Affimed N.V. Transaction History

Ergoteles LLC

  • $68.2 Billion
  • Q3 2023

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.57 - $1.08 $80,541 - $152,604
141,300 New
141,300 $84,000
Q4 2022

Feb 14, 2023
SELL
$1.1 - $2.45 $79,842 - $177,830
-72,584 Reduced 42.95%
96,393 $119,000
Q3 2022

Nov 14, 2022
BUY
$1.96 - $3.32 $331,194 - $561,003
168,977 New
168,977 $348,000
Q2 2022

Aug 12, 2022
SELL
$2.27 - $4.86 $178,195 - $381,510
-78,500 Closed
0 $0
Q1 2022

May 13, 2022
BUY
$3.69 - $5.65 $289,665 - $443,525
78,500 New
78,500 $343,000

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email